Pomegranate juice consumption appears to somewhat enhance inflammatory status and complete blood count in hospitalized COVID-19 patients.
Randomised Controlled Trial Common Cold, Flu & Viral Infections COVID-19 CRP
The study was a randomized, double-blinded placebo-controlled trial involving 48 patients and had two parallel arms. As part of their standard hospital care, patients were either given 500 mL of whole pomegranate juice daily or a placebo for a period of 14 days. The researchers focused on measuring inflammatory indicators and complete blood counts both at the start of the study and at the end of the 14-day intervention period.
Following the 14-day intervention, there was a distinguishable decrease in primary outcomes including inflammatory markers such as C reactive protein, interleukin-6, and erythrocyte sedimentation rate in the group that consumed pomegranate juice as compared to the readings before the intervention. In addition, considerable changes were also observed in secondary outcomes such as neutrophils, lymphocytes, platelets, platelets-to-lymphocyte and neutrophils-to-lymphocyte ratios in the pomegranate juice group compared to the parameters before the intervention. Finally, the mean changes in levels of interleukin-6, white blood cells, neutrophils, lymphocyte, platelets, platelets-to-lymphocyte ratio, blood oxygen saturation and MCV were significantly different between the two groups by the end of intervention, while no significant difference was noted in other blood indices.
View Article